Literature DB >> 23542708

Comparing the Daily Versus the Intermittent Regimens of the Anti-Tubercular Chemotherapy in the Initial Intensive Phase in Non-HIV, Sputum Positive, Pulmonary Tuberculosis Patients.

Pranab Kumar Mandal1, Abhijit Mandal, Sujit Kumar Bhattacharyya.   

Abstract

BACKGROUND: Tuberculosis (TB) is a major health problem in the universe and India is no longer exempted from this crisis .The emergence of HIV and MDRTB (Multi Drug Resistant Tuberculosis) have further made the situation critical. AIMS: Our aim was to compare the efficacy of the daily and the intermittent doses of the Anti Tubercular Drug (ATD) therapy which is under the Revised National Tuberculosis Control Programme, amongst the sputum positive pulmonary tuberculosis in terms of the sputum conversion rate at the end of the initial phase , the default rate and the adverse drug reactions.
METHODS: This was an observational prospective study. MATERIAL: Eighty three patients were selected from the out patient and the inpatient departments of a tertiary medical centre in India.
RESULTS: Forty three cases received an intermittent regimen, where the major age group belonged to the under 40 years age group, the default rate to the therapy was 9.3%, the sputum conversion rate was 94.87% and adverse drug reactions were found in 25.58% of the patients. In the daily regimen, there was an equal proportion of the age group of the patients, both above and below 40 yrs, the sputum conversion rate was 94.74%, a default rate was found in 5% cases and adverse reactions were found in 35% of the cases.
CONCLUSION: Both the intermittent and the daily regimens showed equal sputum conversion rates and the drug default cases were found more in the intermittent group. However, the adverse reactions were found more in the daily regimen category.

Entities:  

Keywords:  Anti tubercular drugs; Daily regimen; Intermittent regimen; Sputum

Year:  2012        PMID: 23542708      PMCID: PMC3592295          DOI: 10.7860/JCDR/2013/5122.2750

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  3 in total

1.  DOTS at a tertiary care center in northern India: successes, challenges and the next steps in tuberculosis control.

Authors:  Mohammad Tahir; S K Sharma; Duncan-Smith Rohrberg; Deepak Gupta; U B Singh; P K Sinha
Journal:  Indian J Med Res       Date:  2006-05       Impact factor: 2.375

2.  Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African/British Medical Research Council Study.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1976-09

3.  ACONCURRENT COMPARISON OF INTERMITTENT (TWICE-WEEKLY) ISONIAZID PLUS STREPTOMYCIN AND DAILY ISONIAZID PLUS PAS IN THE DOMICILIARY TREATMENT OF PULMONARY TUBERCULOSIS; TUBERCULOSIS CHEMOTHERAPY CENTRE, MADRAS.

Authors:  A LOTTE; F HATTON; S PERDRIZET; A ROUILLON
Journal:  Bull World Health Organ       Date:  1964       Impact factor: 9.408

  3 in total
  9 in total

1.  Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children.

Authors:  C K Indumathi; Aruna Sethuraman; Saurav Jain; Savita Krishnamurthy
Journal:  Indian J Pediatr       Date:  2018-12-04       Impact factor: 1.967

2.  Tubercular spondylodiscitis in elderly is a more severe disease: a report of 66 consecutive patients.

Authors:  Ajoy Prasad Shetty; Vibhu Krishnan Viswanathan; Rishi Mukesh Kanna; Rajasekaran Shanmuganathan
Journal:  Eur Spine J       Date:  2017-06-07       Impact factor: 3.134

3.  Intermittent Versus Daily Pulmonary Tuberculosis Treatment Regimens: A Meta-Analysis.

Authors:  Samuel Kasozi; Justin Clark; Suhail A R Doi
Journal:  Clin Med Res       Date:  2015-06-08

4.  Appraisal on patient compliance and factors influencing the daily regimen of anti-tubercular drugs in Mangalore city: A cross-sectional study.

Authors:  Rohith Motappa; Tuba Fathima; Himani Kotian
Journal:  F1000Res       Date:  2022-04-26

5.  Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial.

Authors:  Narendran Gopalan; Ramesh Kumar Santhanakrishnan; Alangudi Natarajan Palaniappan; Pradeep Aravindan Menon; Sekar Lakshman; Padmapriyadarsini Chandrasekaran; Gomathi Narayan Sivaramakrishnan; Devarajulu Reddy; Bhavani Perumal Kannabiran; Hemanth Kumar Kupparam Agiboth; Vijay Krishnamoorthy; Sridhar Rathinam; Chandrasekar Chockalingam; Tamizhselvan Manoharan; MahilMaran Ayyamperumal; Nalini Jayanthi; Kumar Satagopan; Ravichandran Narayanan; Raja Krishnaraja; Sekar Sathiyavelu; Bhanu Kesavamurthy; Chandra Suresh; Murugesan Selvachitiram; Gunasundari Arasan; Stella Susaimuthu; Prabhakaran Rathinam; Prabhakar Angamuthu; Lavanya Jayabal; Lakshmi Murali; Ranjani Ramachandran; Srikanth Prasad Tripathy; Soumya Swaminathan
Journal:  JAMA Intern Med       Date:  2018-04-01       Impact factor: 21.873

6.  Directly-observed and self-administered tuberculosis treatment in a chronic, low-intensity conflict setting in India.

Authors:  Mrinalini Das; Petros Isaakidis; Edward Armstrong; Nirmala Rani Gundipudi; Ramesh B Babu; Ihtesham A Qureshi; Andrea Claes; Anil Kumar Mudimanchi; Nagendra Prasad; Homa Mansoor; Sunita Abraham
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

7.  Self-administered tuberculosis treatment outcomes in a tribal population on the indo-myanmar border, Nagaland, India.

Authors:  Mrinalini Das; Petros Isaakidis; Rahul Shenoy; Rey Anicete; Hemant Kumar Sharma; Imyangluba Ao; Kaikho Osah; Homa Mansoor; Peter Saranchuk; Sunita Abraham
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

8.  Rapid assessment of facilitators and barriers related to the acceptance, challenges and community perception of daily regimen for treating tuberculosis in India.

Authors:  Himanshu Negandhi; Ritika Tiwari; Anjali Sharma; Rajesh Nair; Sanjay Zodpey; Ramesh Reddy Allam; Ganesh Oruganti
Journal:  Glob Health Action       Date:  2017       Impact factor: 2.640

9.  Tuberculosis treatment discontinuation and symptom persistence: an observational study of Bihar, India's public care system covering >100,000,000 inhabitants.

Authors:  Kimberly S Babiarz; Sze-chuan Suen; Jeremy D Goldhaber-Fiebert
Journal:  BMC Public Health       Date:  2014-05-01       Impact factor: 3.295

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.